CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
Amino Acids +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03273712
NCT03273712Phase 2Completed
CompareCT.gov

Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors

University of Iowa·interventional·Posted Sep 6, 2017·Updated Feb 9, 2023

In Brief

A Phase 2 clinical trial evaluating 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, and 1 other intervention for Neuroendocrine Tumors and 3 related conditions. Completed, enrolled 39 participants across 1 site.

Detailed Summary

This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 6, 2017
Enrollment StartSep 29, 2017
Primary CompletionMay 27, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.8 years ago

Interventions

90Y-DOTA tyr3-Octreotideradiation

90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.

68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scanother

68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.

Amino Acidsdrug

This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.